论文部分内容阅读
目的研究新的原发性肝细胞癌(HCC)血清标志物高尔基体蛋白73(GP73)在HCC血清中的表达及临床价值。方法选取确诊为HCC者40例为HCC组;肝炎患者及肝硬化患者120例为肝病组;健康体检者120例为健康组。用双抗体夹心ELISA法检测三组血清GP73浓度;同时检测甲胎蛋白(AFP)及α-L-岩藻糖苷酶(AFU)作对比研究。结果 HCC组血清中GP73的表达水平为(399.17±264.43)ng/ml,显著高于肝病组的(105.12±67.79)ng/ml和健康组的(66.51±46.2)ng/ml,差异均有统计学意义(P<0.05)。GP73、AFP、AFU诊断HCC的敏感性分别为89.28%、62.5%和80.7%;特异性分别为87.1%、78.5%和68.7%,GP73敏感性及特异性均高于AFP和AFU。结论 GP73是继AFP、AFU之后另一个新的优秀的诊断HCC血清标志物,具有重要临床价值。
Objective To investigate the expression and clinical value of GP73, a novel serum of hepatocellular carcinoma (HCC), in serum of HCC patients. Methods Forty patients with HCC were selected as HCC group, 120 patients with hepatitis and cirrhosis as liver disease group and 120 healthy subjects as healthy group. Serum GP73 concentrations were measured by double antibody sandwich ELISA. AFP and α-L-fucosidase (AFU) were also detected for comparison. Results The level of GP73 in HCC group was (399.17 ± 264.43) ng / ml, which was significantly higher than that in liver disease group (105.12 ± 67.79) ng / ml and healthy group (66.51 ± 46.2) ng / ml Significance (P <0.05). The sensitivity of GP73, AFP and AFU for diagnosing HCC were 89.28%, 62.5% and 80.7% respectively; the specificity was 87.1%, 78.5% and 68.7% respectively. The sensitivity and specificity of GP73 were higher than those of AFP and AFU. Conclusion GP73 is another new and excellent serum marker of HCC after AFP and AFU, which has important clinical value.